Document Detail


Potent synergistic interaction between the Nampt inhibitor APO866 and the apoptosis activator TRAIL in human leukemia cells.
MedLine Citation:
PMID:  20696207     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
OBJECTIVE: The nicotinamide phosphoribosyltransferase (Nampt) inhibitor APO866 depletes intracellular nicotinamide adenine dinucleotide (NAD(+)) and shows promising anticancer activity in preclinical studies. Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) binds to plasma membrane receptors DR4 and DR5 and induces apoptosis via caspase-8 and -10. Here we have explored the interaction between APO866 and TRAIL in leukemia cell lines and in primary B-cell chronic lymphocytic leukemia cells.
MATERIALS AND METHODS: Cells were treated with APO866, TRAIL, or their combination. Viability and mitochondrial transmembrane potential (ΔΨ(m)) were determined by cell staining with propidium iodide and tetramethylrhodamine ethyl ester, respectively, and flow cytometry. Nampt and γ-tubulin levels, as well as caspase-3 cleavage were detected by immunoblotting. DR4 and DR5 expression were assessed by immunostaining and flow cytometry. Caspases were inhibited with zVAD-FMK and zDEVD-FMK; autophagy with 3-methyladenine, LY294002, and wortmannin. Intracellular NAD(+) and adenosine triphosphate (ATP) were measured by cycling assays and high-performance liquid chromatography (HPLC), respectively.
RESULTS: APO866 induced NAD(+) depletion, ΔΨ(m) dissipation, and ATP shortage in leukemia cells, thereby leading to autophagic cell death. TRAIL induced caspase-dependent apoptosis. TRAIL addition to APO866 synergistically increased its activity in leukemia cells by enhancing NAD(+) depletion, ΔΨ(m) dissipation, and ATP shortage. No DR5 upregulation at the cell surface in response to APO866 was observed. Remarkably, in healthy leukocytes APO866 and TRAIL were poorly active and failed to show any cooperation.
CONCLUSIONS: Activation of the extrinsic apoptotic cascade with TRAIL selectively amplifies the sequelae of Nampt inhibition in leukemia cells, and appears as a promising strategy to enhance APO866 activity in hematological malignancies.
Authors:
Gabriele Zoppoli; Michele Cea; Debora Soncini; Floriana Fruscione; Justine Rudner; Eva Moran; Irene Caffa; Davide Bedognetti; Giulia Motta; Riccardo Ghio; Fabio Ferrando; Alberto Ballestrero; Silvio Parodi; Claus Belka; Franco Patrone; Santina Bruzzone; Alessio Nencioni
Related Documents :
20451517 - Compound c sensitizes caki renal cancer cells to trail-induced apoptosis through reacti...
18927587 - Hepatitis b virus core protein inhibits trail-induced apoptosis of hepatocytes by block...
15611657 - Cell death inhibiting rna (cdir) modulates ifn-gamma-stimulated sensitization to fas/cd...
17432717 - Enhanced proapoptotic effects of tumor necrosis factor-related apoptosis-inducing ligan...
21115047 - Il-27 induces the differentiation of tr1-like cells from human naive cd4(+) t cells via...
20021667 - Short-term cultured, interleukin-15 differentiated dendritic cells have potent immunost...
Publication Detail:
Type:  Journal Article     Date:  2010-08-07
Journal Detail:
Title:  Experimental hematology     Volume:  38     ISSN:  1873-2399     ISO Abbreviation:  Exp. Hematol.     Publication Date:  2010 Nov 
Date Detail:
Created Date:  2010-10-22     Completed Date:  2010-12-30     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  0402313     Medline TA:  Exp Hematol     Country:  Netherlands    
Other Details:
Languages:  eng     Pagination:  979-88     Citation Subset:  IM    
Copyright Information:
Copyright © 2010 ISEH - Society for Hematology and Stem Cells. Published by Elsevier Inc. All rights reserved.
Affiliation:
Department of Internal Medicine, University of Genoa, Genoa, Italy.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Acrylamides / pharmacology*
Adenosine Triphosphate / metabolism
Aged
Apoptosis / drug effects
Autophagy / drug effects
Caspase 3 / metabolism
Cell Line, Tumor
Cells, Cultured
Cytokines / antagonists & inhibitors,  metabolism
Drug Synergism
Female
Humans
Immunoblotting
Jurkat Cells
Leukemia / metabolism,  pathology
Leukemia, Lymphocytic, Chronic, B-Cell / blood,  pathology
Leukocytes, Mononuclear / drug effects*,  metabolism
Male
Membrane Potential, Mitochondrial / drug effects
Middle Aged
NAD / metabolism
Nicotinamide Phosphoribosyltransferase / antagonists & inhibitors,  metabolism
Piperidines / pharmacology*
Receptors, TNF-Related Apoptosis-Inducing Ligand / metabolism
TNF-Related Apoptosis-Inducing Ligand / pharmacology*
Tubulin / metabolism
Chemical
Reg. No./Substance:
0/Acrylamides; 0/Cytokines; 0/N-(4-(1-benzoylpiperidin-4-yl)butyl)-3-(pyridin-3-yl)acrylamide; 0/Piperidines; 0/Receptors, TNF-Related Apoptosis-Inducing Ligand; 0/TNF-Related Apoptosis-Inducing Ligand; 0/Tubulin; 53-84-9/NAD; 56-65-5/Adenosine Triphosphate; EC 2.4.2.12/Nicotinamide Phosphoribosyltransferase; EC 2.4.2.12/nicotinamide phosphoribosyltransferase, human; EC 3.4.22.-/Caspase 3

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Role of a novel zebrafish nup98 during embryonic development.
Next Document:  Establishment of an erythroid cell line from primary CD36+ erythroid progenitor cells.